Antibody designed to prevent clotting: Erik Westein and Christoph Hagemeyer explain their research скачать в хорошем качестве

Antibody designed to prevent clotting: Erik Westein and Christoph Hagemeyer explain their research

Heart attack and stroke remain the leading causes of mortality and morbidity worldwide. Current anti-thrombotic therapies still suffer from severe bleeding side effects which limit the use of higher doses. Dr Erik Westein and Associate Professor Christoph Hagemeyer are senior authors on a paper in Haematologica which describes how they designed a unique antibody which inhibits a blood-borne protein, Von Willebrand Factor, to prevent thrombosis (dangerous clotting) without preventing normal clotting, thereby reducing excess bleeding. Story: http://ccsmonash.blogspot.com/2020/09... Reference: Thomas Hoefer, Akshita Rana, Be'eri Niego, Shweta Jagdale, Hugo J Albers, Elizabeth E Gardiner, Robert K Andrews, Andries D van der Meer, Christoph E Hagemeyer, and Erik Westein. Targeting shear gradient activated von Willebrand Factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro. https://www.haematologica.org/article... Nanobiotechnology lab/Hagemeyer group: https://www.monash.edu/medicine/ccs/b...